Article · Journal · 2025

Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study

Journal of sickle cell disease.

Citations: 1from other works
Field-weighted impact: 0.621.00 is the world average for its field and year
Among its field: 75th percentileby citations, against works of its field and year
Authors: 20from 10 institutions

Authors

20 authors across 10 institutions in 2 countries